Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal

Key Points

• This research aims to evaluate the comparative usage and financial effects of branded versus generic dapagliflozin in Medicaid.
• Cross-sectional study design evaluating branded vs generic dapagliflozin utilization under Medicaid fee-for-service and managed care structures.
• Increased utilization of authorized generics was observed post Medicaid rebate cap removal.
• Significant financial savings were identified for Medicaid programs transitioning to generic dapagliflozin.